losartan has been researched along with paclitaxel in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eliasson, E; Hayakawa, T; Inotsume, N; Mukai, Y; Rane, A; Toda, T | 1 |
| Eliasson, E; Hayakawa, T; Inotsume, N; Mukai, Y; Rane, A; Senda, A; Toda, T | 1 |
| Chen, J; Gao, H; He, Q; Liu, Y; Qiu, Y; Ruan, S; Tai, X; Wang, Y; Xia, T; Yang, Y; Zhang, L; Zhang, Q | 1 |
| Eliasson, E; Inotsume, N; Mukai, Y; Rane, A; Senda, A; Toda, T | 1 |
| Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z | 1 |
| Gao, H; He, Q; Liu, J; Ma, L; Shi, K; Wang, Y; Xia, T; Yu, Q; Zhang, L; Zhang, Q | 1 |
| Chen, SY; Chiang, CS; Kao, TH; Lai, YH | 1 |
| Abdi, S; Hwang, SH; Kim, E; Kim, HK | 1 |
| Diallo, M; Kalynovska, N; Palecek, J; Sotakova-Kasparova, D | 1 |
1 review(s) available for losartan and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for losartan and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Agents, Phytogenic; Cells, Cultured; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Humans; Losartan; Microsomes; Paclitaxel | 2014 |
Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Genotype; Humans; In Vitro Techniques; Losartan; Microsomes, Liver; Paclitaxel | 2015 |
High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Endocytosis; Evans Blue; Female; Humans; Hydrogen-Ion Concentration; Liposomes; Losartan; Mice, Inbred BALB C; Paclitaxel; Particle Size; Static Electricity; Tissue Distribution; Treatment Outcome | 2015 |
The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Genotype; Humans; Inhibitory Concentration 50; Losartan; Microsomes, Liver; Paclitaxel; Taxoids | 2016 |
Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Hydrogen-Ion Concentration; Liposomes; Losartan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Protein-Lysine 6-Oxidase | 2016 |
Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Collagen; Drug Delivery Systems; Female; Hydrogen-Ion Concentration; Liposomes; Losartan; Mice; Mice, Inbred BALB C; Paclitaxel; Peptides | 2018 |
Dual-drug nanomedicine with hydrophilic F127-modified magnetic nanocarriers assembled in amphiphilic gelatin for enhanced penetration and drug delivery in deep tumor tissue.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Gelatin; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Losartan; Nanomedicine; Nanoparticles; Paclitaxel; Polyethylenes; Polypropylenes; Spheroids, Cellular; Tumor Microenvironment | 2018 |
Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cytokines; Disease Models, Animal; Ganglia, Spinal; Glial Fibrillary Acidic Protein; Hyperalgesia; Hypnotics and Sedatives; Inflammation Mediators; Losartan; Male; Neuralgia; Neurons; NF-kappa B; Paclitaxel; Phosphorylation; Rats, Sprague-Dawley | 2019 |
Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Ganglia, Spinal; Losartan; Macrophages; Male; Neuralgia; Paclitaxel; Pain Management; Rats | 2020 |